Product Description: Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate targeting HER2, with an effective payload connected via a linker (LP, HY-148067) to a STING agonist (STING agonist-20, HY-148068), and has potential immune activation and anticancer activity[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Duvall J R, et al. XMT-2056, a HER2-targeted Immunosynthen STING-agonist antibody-drug conjugate, binds a novel epitope of HER2 and shows increased anti-tumor activity in combination with trastuzumab and pertuzumab[J]. Cancer Res, 2022, 82(12_Supplement): 3503-3503.
CAS Number: 2847102-44-5
Molecular Weight: N/A
Research Area: Cancer; Inflammation/Immunology
Target: Antibody-Drug Conjugates (ADCs);EGFR;STING